Literature DB >> 3905783

Arabinosylnucleoside 5'-triphosphate inhibits DNA primase of calf thymus.

S Yoshida, R Suzuki, S Masaki, O Koiwai.   

Abstract

It has been shown that DNA primase activity is tightly associated with 10S DNA polymerase alpha from calf thymus and that the ribonucleotide-dependent DNA synthesis is more sensitive to araCTP than DNA-primed DNA synthesis (Yoshida, S., et al. (1983) Biochim. Biophys. Acta 741, 348-357). Here we measured DNA primase activity using poly(dT) template or M13 bacteriophage single-stranded DNA template and primer RNA synthesis was coupled to the reaction by Escherichia coli DNA polymerase I Klenow fragment. By this method, the primer RNA synthesis can be measured independently of the associating DNA polymerase alpha. Using poly(dT) template, it was found that arabinosyladenine 5'-triphosphate (araATP) strongly inhibited DNA primase in competition with rATP. The apparent Ki for araATP was 21 microM and the ratio of Ki/Km (for rATP) was as low as 0.015. With poly(dI, dT) or M13 DNA, it was shown that araCTP also inhibited DNA primase in the similar manner. Product analysis using [alpha-32P]rATP showed that araATP inhibited the elongation of primer RNA. However, it is not likely that arabinosylnucleotides act as chain-terminators, since incubation of primer RNA with araATP did not abolish its priming activity. From these results, it is suggested that arabinosylnucleotide inhibits the initiation as well as elongation of Okazaki fragments in mammalian cells.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3905783     DOI: 10.1093/oxfordjournals.jbchem.a135297

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  1 in total

1.  Structural Basis for Inhibition of Human Primase by Arabinofuranosyl Nucleoside Analogues Fludarabine and Vidarabine.

Authors:  Sandro Holzer; Neil J Rzechorzek; Isobel R Short; Michael Jenkyn-Bedford; Luca Pellegrini; Mairi L Kilkenny
Journal:  ACS Chem Biol       Date:  2019-09-11       Impact factor: 5.100

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.